Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 19/20 | 0.59 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13780494 | 1.00 | SLC6A9 (0.59) | SLC6A9SLC6A5L3MBTL1 | |
| SCHEMBL31676491 | 1.00 | SLC6A9 (0.59) | SLC6A9SLC6A5L3MBTL1 | |
| SCHEMBL31676524 | 0.93 | SLC6A9 (0.55) | SLC6A9SLC6A5L3MBTL1 | |
| SCHEMBL3234800 | 0.92 | SLC6A9 (0.51) | SLC6A9SLC6A5L3MBTL1 | |
| SCHEMBL13303708 | 0.92 | SLC6A9 (0.53) | SLC6A9SLC6A5L3MBTL1 | |
| SCHEMBL3236079 | 0.92 | SLC6A9 (0.51) | SLC6A9SLC6A5 | |
| SCHEMBL3034321 | 0.91 | SLC6A9 (0.49) | SLC6A9SLC6A5L3MBTL1 | |
| SCHEMBL3236708 | 0.90 | SLC6A9 (0.48) | SLC6A9SLC6A5 | |
| SCHEMBL3233042 | 0.90 | SLC6A9 (0.52) | SLC6A9SLC6A5 | |
| SCHEMBL13780780 | 0.89 | SLC6A9 (0.54) | SLC6A9SLC6A5L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11813257-B2 | Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors | DISC MEDICINE, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11813257-B2 | Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors | DISC MEDICINE, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20210283129-A1 | METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH GLYCINE TRANSPORT INHIBITORS | DISC MEDICINE, INC. | 2021-09-16 | — | — | US | disclosed |
| US-7745642-B2 | Glycine transport inhibitors | GLAXO GROUP LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-7745642-B2 | Glycine transport inhibitors | GLAXO GROUP LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-7745642-B2 | Glycine transport inhibitors | GLAXO GROUP LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-20090175788-A1 | RADIOLABELLED LIGAND FOR THE GLYCINE 1 TRANSPORTER | GLAXO GROUP LIMITED (GB) | 2009-07-09 | — | — | US | disclosed |
| EP-2032512-A1 | RADIOLABELLED LIGAND FOR THE GLYCINE 1 TRANSPORTER | Glaxo Group Limited (GB) | 2009-03-11 | — | — | EP | disclosed |
| US-20080287547-A1 | Glycine Transport Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| US-20080287547-A1 | Glycine Transport Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| US-20080287547-A1 | Glycine Transport Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| WO-2007147838-A1 | RADIOLABELLED LIGAND FOR THE GLYCINE 1 TRANSPORTER | GLAXO GROUP LIMITED (GB) | 2007-12-27 | — | — | WO | disclosed |
| EP-1841727-A1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006067423-A1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210283129-A1 | METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH GLYCINE TRANSPORT INHIBITORS | GFPT1, MPST, XPNPEP1 | SLC6A9 19/4885SLC6A5 25/4885L3MBTL1 1058/4885 |
| US-20080287547-A1 | Glycine Transport Inhibitors | SLC18A2, SLC6A5, SLC1A2 | SLC6A9 13/4885SLC6A5 2/4885L3MBTL1 3944/4885 |
| US-20090175788-A1 | RADIOLABELLED LIGAND FOR THE GLYCINE 1 TRANSPORTER | SLC7A1, GLRA1, SLC6A5 | SLC6A9 5/4885SLC6A5 3/4885L3MBTL1 299/4885 |
| US-11813257-B2 | Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors | GFPT1, MPST, XPNPEP1 | SLC6A9 19/4885SLC6A5 25/4885L3MBTL1 1058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.